Abstract

Lipedema is a disease with high prevalence but low recognition. It is often misdiagnosed and underdiagnosed. Obesity and lymphoedema are the most common differential diagnoses and can also coexist in patient with lipedema. Its broad range of presentation and fat distribution types contribute to this confusion. It is likely that lipedema symptom variations and presentation forms are often associated with hormonal variations, chronic low-grade systemic inflammation, and wide polygenic variations. This paper presents a theory regarding the clinical evolution of lipedema clinical and its involvement with other diseases, suggesting a three-phase approach for treatment.

Keywords: Lipedema; Obesity; Lymphoedema

References

1. Wold L., et al. “Lipedema of the legs: a syndrome characterized by fat legs and edema”. Annals of Internal Medicine 34 (1951): 1243-1250.
2. Allen EV., et al. “Lipedema of the legs: a syndrome characterized by fat legs and orthostatic edema”. Proceedings of the staff meetings of the Mayo Clinic 15 (1940): 184-187.
3. Buck DW and Herbst KL. “Lipedema: A Relatively Common Disease with Extremely Common Misconceptions”. Plastic and Reconstructive Surgery – Global Open 4 (2016): e1043.
4. Campos Moraes Amato A and Benitti DA. “Lipedema”. In: SECAD (2018): 1-22.
5. Moraes IN. “Cânones da beleza”. Rev Cult e Saude 1 (2003): 25-30.
6. Goodliffe JM., et al. “An under-diagnosed cause of leg swelling”. British Medical Journal Case Reports (2013)”. 
7. Child AH., et al. “Lipedema: An inherited condition”. American Journal of Medical Genetics Part A 152 (2010): 970-976.
8. Rapprich S., et al. “Liposuktion ist eine wirksame Therapie beim Lipödem - Ergebnisse einer Untersuchung mit 25 Patientinnen”. Journal of the German Society of Dermatology 9 (2011): 33-41.
9. McClellan J and King MC. “Genetic heterogeneity in human disease”. Cell 141 (2010): 210-217.
10. Hofuku I., et al. “An introduction of the node-clustering algorithm using the PH algorithm”. Inf 16 (2013): 8597-8610.
11. Bano G., et al. “Pit-1 Mutation and Lipoedema in a Family”. Experimental and Clinical Endocrinology and Diabetes 118 (2009): 377-380.
12. Szél E., et al. “Pathophysiological dilemmas of lipedema”. Medical Hypotheses 83 (2014): 599-606.
13. Calvano SE., et al. “A network-based analysis of systemic inflammation in humans”. Nature 437 (2005): 1032-1037.
14. Guthrie GJK., et al. “The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer”. Critical Reviews in Oncology/Hematology 88 (2013): 218-230.
15. Dolan RD., et al. “The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: Comparison of composite ratios and cumulative scores”. British Journal of Cancer 119 (2018): 40-51.
16. McMillan DC. “The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer”. Cancer Treatment Reviews 39 (2013): 534-540.
17. Mathur N and Pedersen BK. “Exercise as a mean to control low-grade systemic inflammation”. Mediators of Inflammation (2008).
18. Pedersen BK and Saltin B. “Evidence for prescribing exercise as therapy in chronic disease”. Scandinavian Journal of Medicine and Science in Sports 16 (2006): 3-63.
19. Alwardat N., et al. “The effect of lipedema on health-related quality of life and psychological status: a narrative review of the literature”. Eating and Weight Disorders (2019): 1-6.
20. LaMonte MJ., et al. “Physical activity and diabetes prevention”. Journal of Applied Physiology 99 (2005): 1205-1213.
21. Thune I and Furberg A-S. “Physical activity and cancer risk: dose-response and cancer, all sites and site-specific”. Medicine and Science in Sports and Exercise 33 (2001): S530-S550.
22. Wilund KR. “Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?”. Clinical Science 112 (2007): 543-555.
23. Pedersen BK. “State of the Art Reviews: Health Benefits Related to Exercise in Patients With Chronic Low-Grade Systemic Inflammation”. American Journal of Lifestyle Medicine 1 (2007): 289-298.
24. Petersen AMW and Pedersen BK. “The anti-inflammatory effect of exercise”. Journal of Applied Physiology 98 (2005): 1154-1162.
25. Febbraio MA and Pedersen BK. “Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?”. Exercise and Sport Sciences Reviews 33 (2005): 114-119.
26. Pedersen BK., et al. “Searching for the exercise factor: is IL-6 a candidate?”. Journal of Muscle Research and Cell Motility 24 (2003): 113-119.
27. Edwards KM., et al. “The Acute Stress-Induced Immunoenhancement Hypothesis”. Exercise and Sport Sciences Reviews (2007): 150-155.
28. Bruunsgaard H. “Physical activity and modulation of systemic low-level inflammation”. Journal of Leukocyte Biology 78 ( 2005): 819-835.
29. Gil A., et al. “Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity”. British Journal of Nutrition 98 (2007): 121-126.
30. Bulló M., et al. “Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression”. Obesity Research 11 (2003): 525-531.
31. Coppack SW. “Pro-inflammatory cytokines and adipose tissue”. Proceedings of the Nutrition Society 60 (2001): 349-356.
32. Zeyda M., et al. “Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production”. International Journal of Obesity 31 (2007): 1420-1428.
33. Dandona P., et al. “Inflammation the link between insulin resistance”. Trends in Immunology 25 (2004): 4-7.
34. Gleeson MM. “Immune function in sport and exercise”. Journal of Applied Physiology 103 (2007): 693-699.
35. Pedersen BK and Fischer CP. “Physiological roles of muscle-derived interleukin-6 in response to exercise”. Current Opinion in Clinical Nutrition and Metabolic Care 10 (2007): 265-271.
36. Alexandraki K., et al. “Inflammatory process in type 2 diabetes: The role of cytokines”. Annals of the New York Academy of Sciences 1084 (2006): 89-117.
37. Van Guilder GP., et al. “Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults”. Obesity 14 (2006): 2127-2131.
38. Bennet AM., et al. “Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction”. Atherosclerosis 171 (2003): 359-367.
39. Cook NR., et al. “The effect of including C-reactive protein in cardiovascular risk prediction models for women”. Annals of Internal Medicine 145 (2006): 21-29.
40. Cholesterol CPL., et al. “Cholesterol Levels in the Prediction of First Cardiovascular Events”. The New Zealand Medical Journal 347 (2002): 1557-1565.
41. Van Hall G., et al. “Interleukin-6 stimulates lipolysis and fat oxidation in humans”. The Journal of Clinical Endocrinology and Metabolism 88 (2003): 3005-3010.
42. Petersen EW. “Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro”. American Journal of Physiology-Endocrinology and Metabolism 288 (2004): E155-E162.
43. Duncan BB., et al. “Low-Grade Systemic Inflammation and the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study”. Diabetes 52 (2003): 1799-1805.
44. Trayhurn P and Beattie JH. “Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ”. Proceedings of the Nutrition Society 60 (2001): 329-339.
45. Uysal KT., et al. “Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function”. Nature 389 (1997): 610-614.
46. Steinberg HO., et al. “Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the Syndrome of Insulin Resistance”. Journal of Clinical Investigation 97 (1996): 2601-2610.
47. Mochida-Nishimura K., et al. “Differential Activation of Map Kinase Signaling Pathways and Nuclear Factor-Kappab in Bronchoalveolar Cells of Smokers and Nonsmokers”. Molecular Medicine 7 (2001): 177-185.
48. Heusch WL and Maneckjee R. “Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells”. Carcinogenesis 19 (1998): 551-556.
49. Hirosumi J., et al. “A central, role for JNK in obesity and insulin resistance”. Nature 420 (2002): 333-336.
50. Libert C. “Inflammation: A nervous connection”. Nature 421 (2003): 328-329.
51. Savage S., et al. “Effects of cigarette smoke on the immune system”. Toxicology and Applied Pharmacology 111 (1991): 523-529.
52. Wang H., et al. “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation”. Nature 421 (2003): 384-388.